. 2021 Aug 3;21:310. doi: 10.1186/s12876-021-01880-9

Table 5.

Demographic and clinical characteristics for the different genotypes of rs55646866 in CD patients

	rs55646866 CC	rs55646866 CT	rs55646866 TT	p value (Fisher or Kruskal–Wallis)
Gender
Male (n = 488) Female (n = 493)	394 (50.2%) 391 (49.8%)	81 (46.8%) 92 (53.2%)	13 (56.5%) 10 (43.5%)	0.605
Age at diagnosis [years]
Median, q25–q75, Min–max	24.3, 17.9–34.4, 1.1–81.4	24.4, 18.5–33.0, 0.8–65.9	25.0, 18.7–31.5, 11.5–73.7	0.875
Disease duration [years]
Median, q25–q75, Min–max	12.2, 7.0–20.9, 0.1–56.6	12.8, 7.6–23.5, 1.2–44.7	6.1, 4.5–13.1, 1.5–33.8	0.030
Complications*
No (n = 345) Yes (n = 636)	281 (35.8%) 504 (64.2%)	56 (32.4%) 117 (67.6%)	8 (34.8%) 15 (65.2%)	0.727
Fistula, abscess or anal fissure*
No (n = 518) Yes (n = 463)	411 (52.4%) 374 (47.6%)	94 (54.3%) 79 (45.7%)	13 (56.5%) 10 (43.5%)	0.836
Focus on the “yes”:
Perianal fistula Other fistula Fissure Abscess	199 (53.2%) 144 (38.5%) 113 (30.2%) 203 (54.3%)	38 (48.1%) 36 (45.6%) 24 (30.4%) 44 (55.7%)	6 (60.0%) 3 (30.0%) 3 (30.0%) 6 (60.0%)	0.641 0.439 1.000 0.930
Surgery	195 (52.1%)	46 (58.2%)	5 (50.0%)	0.626
Stenosis*
No (n = 551) Yes (n = 430)	446 (56.8%) 339 (43.2%)	95 (54.9%) 78 (45.1%)	10 (43.5%) 13 (56.5%)	0.413
Focus on the “yes”:
Operation Dilation No intervention	169 (49.9%) 133 (39.2%) 189 (55.8%)	44 (56.4%) 33 (42.3%) 40 (51.3%)	8 (61.5%) 3 (23.1%) 7 (53.8%)	0.460 0.434 0.766
CDAI—maximal value throughout follow-up
Median, q25–q75, Min–max	64, 28–114, 0–435	76, 33–131, 6–479	64, 50–117, 6–280	0.108
Reported flare*
No (n = 477) Yes (n = 504)	387 (49.3%) 398 (50.7%)	82 (47.4%) 91 (52.6%)	8 (34.8%) 15 (65.2%)	0.365
Flare possibly or highly related to (focus on yes):
NSAIDs Antibiotics GI tract infection Other infection Treatment decr./disc Other medication	8 (2.0%) 8 (2.0%) 63 (15.8%) 25 (6.3%) 100 (25.1%) 4 (1.0%)	2 (2.2%) 0 (0%) 20 (22.0%) 11 (12.1%) 29 (31.9%) 3 (3.3%)	1 (6.7%) 1 (6.7%) 1 (6.7%) 1 (6.7%) 5 (33.3%) 0 (0%)	0.450 0.154 0.255 0.143 0.319 0.292
Flare management (focus on the yes):
Hospitalization Ambulatory Surgery Drug therapy	68 (17.1%) 96 (24.1%) 39 (9.8%) 344 (86.4%)	16 (17.6%) 31 (34.1%) 11 (12.1%) 81 (89.0%)	2 (13.3%) 2 (13.3%) 0 (0%) 13 (86.7%)	0.967 0.090 0.443 0.776
Focus on the hospitalizations:
Total days of hosp. Median, q25–q75, Min–max	7.5, 2–16, 0–55	3.5, 0–17.5, 0–86	4, 3–5, 3–5	0.553

rs55646866
CC

rs55646866
CT

rs55646866
TT

p value (Fisher or Kruskal–Wallis)

Gender

Male (n = 488)

Female (n = 493)

394 (50.2%)

391 (49.8%)

81 (46.8%)

92 (53.2%)

13 (56.5%)

10 (43.5%)

0.605

Age at diagnosis [years]

Median, q25–q75,

Min–max

24.3, 17.9–34.4,

1.1–81.4

24.4, 18.5–33.0,

0.8–65.9

25.0, 18.7–31.5,

11.5–73.7

0.875

Disease duration [years]

Median, q25–q75,

Min–max

12.2, 7.0–20.9,

0.1–56.6

12.8, 7.6–23.5,

1.2–44.7

6.1, 4.5–13.1,

1.5–33.8

0.030

Complications*

No (n = 345)

Yes (n = 636)

281 (35.8%)

504 (64.2%)

56 (32.4%)

117 (67.6%)

8 (34.8%)

15 (65.2%)

0.727

Fistula, abscess or anal fissure*

No (n = 518)

Yes (n = 463)

411 (52.4%)

374 (47.6%)

94 (54.3%)

79 (45.7%)

13 (56.5%)

10 (43.5%)

0.836

Focus on the “yes”:

Perianal fistula

Other fistula

Fissure

Abscess

199 (53.2%)

144 (38.5%)

113 (30.2%)

203 (54.3%)

38 (48.1%)

36 (45.6%)

24 (30.4%)

44 (55.7%)

6 (60.0%)

3 (30.0%)

6 (60.0%)

0.641

0.439

1.000

0.930

Surgery

195 (52.1%)

46 (58.2%)

5 (50.0%)

0.626

Stenosis*

No (n = 551)

Yes (n = 430)

446 (56.8%)

339 (43.2%)

95 (54.9%)

78 (45.1%)

10 (43.5%)

13 (56.5%)

0.413

Focus on the “yes”:

Operation

Dilation

No intervention

169 (49.9%)

133 (39.2%)

189 (55.8%)

44 (56.4%)

33 (42.3%)

40 (51.3%)

8 (61.5%)

3 (23.1%)

7 (53.8%)

0.460

0.434

0.766

CDAI—maximal value throughout follow-up

Median, q25–q75,

Min–max

64, 28–114,

0–435

76, 33–131,

6–479

64, 50–117,

6–280

0.108

Reported flare*

No (n = 477)

Yes (n = 504)

387 (49.3%)

398 (50.7%)

82 (47.4%)

91 (52.6%)

8 (34.8%)

15 (65.2%)

0.365

Flare possibly or highly related to (focus on yes):

NSAIDs

Antibiotics

GI tract infection

Other infection

Treatment decr./disc

Other medication

8 (2.0%)

63 (15.8%)

25 (6.3%)

100 (25.1%)

4 (1.0%)

2 (2.2%)

0 (0%)

20 (22.0%)

11 (12.1%)

29 (31.9%)

3 (3.3%)

1 (6.7%)

5 (33.3%)

0 (0%)

0.450

0.154

0.255

0.143

0.319

0.292

Flare management (focus on the yes):

Hospitalization

Ambulatory

Surgery

Drug therapy

68 (17.1%)

96 (24.1%)

39 (9.8%)

344 (86.4%)

16 (17.6%)

31 (34.1%)

11 (12.1%)

81 (89.0%)

2 (13.3%)

0 (0%)

13 (86.7%)

0.967

0.090

0.443

0.776

Focus on the hospitalizations:

Total days of hosp.

Median, q25–q75,

Min–max

7.5, 2–16,

0–55

3.5, 0–17.5,

0–86

4, 3–5,

3–5

0.553

Bold indicates a significant p-value (p < 0.05)